Maxim Group's healthcare analyst Jason Kolbert has high hopes for Gilead Sciences, Inc. (NASDAQ:GILD), reiterating a Buy recommendation on the stock with a 12-month price target of …
It’s been an eventful week on the pipeline front with companies like Biogen Inc (NASDAQ:BIIB), Prothena Corporation PLC (NASDAQ:PRTA) and Vertex Pharmaceuticals Incorporated …
Gilead Sciences Inc (NASDAQ: GILD) issued a new warning about its hepatitis C drugs after discovering a dangerous interaction with amiodarone, a drug that …
William Blair's healthcare analyst John Sonnier came out today with a few insights on Gilead Sciences, Inc. (NASDAQ:GILD), after the company sent warnings to health providers about potentially fatal risks …
Just a day after Retrophin Inc. (NASDAQ:RTRX) announced a $100 million financing the U.
